We are live on ! Find out more
KLRS

Kalaris Therapeutics
KLRS

81 hedge funds and large institutions have $28.8M invested in Kalaris Therapeutics in 2023 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,580% more call options, than puts

Call options by funds: $284K | Put options by funds: $5K

10% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 20

0.43% less ownership

Funds ownership: 2.05% → 1.62% (-0.43%)

10% less funds holding

Funds holding: 90 → 81 (-9)

26% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 35

75% less capital invested

Capital invested by funds: $115M → $28.8M (-$86.7M)

Holders
81
Holders Change
-9
Holders Change %
-10%
% of All Funds
1.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
22
Reduced
20
Closed
35
Calls
$284K
Puts
$5K
Net Calls
+$279K
Net Calls Change
+$322K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$5.42M
2
Morgan Stanley
Morgan Stanley
New York
+$808K
3
WP
Woodline Partners
California
+$762K
4
Renaissance Technologies
Renaissance Technologies
New York
+$734K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$433K

Top Sellers

Rank Fund Capital Flow
1
Alkeon Capital Management
Alkeon Capital Management
New York
-$9.9M
2
GC
GMT Capital
Georgia
-$9.05M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.84M
4
WA
Wasatch Advisors
Utah
-$4.35M
5
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$1.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIP
76
Ameritas Investment Partners
Nebraska
$1.64K – – –
Federated Hermes
77
Federated Hermes
Pennsylvania
$1.34K +$3.35K +85 New
Lazard Asset Management
78
Lazard Asset Management
New York
$1K -$237 -6 -6%
PA
79
Parallel Advisors
California
$778 – – –
Nisa Investment Advisors
80
Nisa Investment Advisors
Missouri
$483 -$118 -3 -9%
PNC Financial Services Group
81
PNC Financial Services Group
Pennsylvania
$86 +$197 +5 New
Alkeon Capital Management
82
Alkeon Capital Management
New York
– -$9.9M -200,222 Closed
GC
83
GMT Capital
Georgia
– -$9.05M -183,099 Closed
Massachusetts Financial Services
84
Massachusetts Financial Services
Massachusetts
– -$1.79M -36,125 Closed
Wellington Management Group
85
Wellington Management Group
Massachusetts
– -$1.28M -25,975 Closed
UOC
86
UBS O'Connor
Illinois
– -$495K -10,000 Closed
N
87
Nuveen
North Carolina
– -$351K -7,092 Closed
ECM
88
ExodusPoint Capital Management
New York
– -$247K -5,005 Closed
Swiss National Bank
89
Swiss National Bank
Switzerland
– -$241K -4,883 Closed
State of Wisconsin Investment Board
90
State of Wisconsin Investment Board
Wisconsin
– -$180K -3,645 Closed
Verition Fund Management
91
Verition Fund Management
Connecticut
– -$146K -2,945 Closed
CIC
92
Cornercap Investment Counsel
Georgia
– -$141K -2,846 Closed
CS
93
Credit Suisse
Switzerland
– -$113K -2,283 Closed
JF
94
Jump Financial
Illinois
– -$78.3K -1,582 Closed
RCM
95
Regency Capital Management
Hawaii
– -$64.6K -1,305 Closed
QI
96
Qtron Investments
Massachusetts
– -$59.2K -1,197 Closed
UBS AM
97
UBS AM
Illinois
– -$50.9K -1,029 Closed
MIM
98
MetLife Investment Management
New Jersey
– -$45.8K -927 Closed
SSG
99
Summit Securities Group
New York
– -$43K -873 Closed
SEI Investments
100
SEI Investments
Pennsylvania
– -$42.4K -856 Closed
1 2 3
4
5

KLRS Hedge Fund Activity: Q4 2023 in Review

81 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q4 2023, worth a combined $28.8M — down 75% from $115M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of KLRS and 26 opened new positions — a net loss of 9 holders — while 20 trimmed existing stakes and 22 added.

The largest buyer was Millennium Management, adding an estimated $5.42M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $9.9M sold.

  • 81 institutional investors held Kalaris Therapeutics (KLRS) as of Q4 2023, down from 90 in Q3 2023.
  • Funds reported $28.8M of Kalaris Therapeutics stock for Q4 2023, down 75% quarter-over-quarter.
  • 26 funds opened new Kalaris Therapeutics positions in Q4 2023 and 35 closed out, a net change of -9 holders.
  • The largest Kalaris Therapeutics buyer in Q4 2023 was Millennium Management, an estimated $5.42M added.
  • The largest Kalaris Therapeutics seller in Q4 2023 was Alkeon Capital Management, an estimated $9.9M sold.

Based on aggregated 13F filings for Q4 2023.